Table 3 Study endpoints
6 month after T0 | 1, 2 and 3 years after T0 | |
|---|---|---|
Primary endpoint | ||
• SPPB score | X | |
Secondary Endpoints | ||
• SPPB score | X | |
• Handgrip test | X | |
• All-cause mortality | X | |
• Cardiovascular mortality | X | |
• All-cause re-hospitalization | X | |
• Cardiovascular re-hospitalization | X | |
• aADL score | X | X |
• PAR Questionnaire | X | X |
• LDL- cholesterol level | X | |
• EQ-5D score | X | X |
• Glycated Haemoglobin (HbA1C) level | X | X |
• On treatment platelet reactivity | X | X |
• Nuisance bleedings | X | X |